Myopia is on the rise, and so is high myopia. By 2050, myopia is projected to affect half the global population, and up to 10% of those individuals are expected to develop high myopia.¹. These higher levels of myopia bring significantly increased risks of complications later in life, such as glaucoma and retinal detachment. While myopia management solutions are available, patients with high myopia have historically had fewer options.
That’s why HOYA Vision Care Canada is proud to introduce the MiYOSMART Extended Range. This expansion brings MiYOSMART technology to even more patients, supporting eye care professionals (ECPs) to provide effective myopia management for a broader range of prescriptions. At HOYA, every diopter counts, because every myopic patient counts.
MiYOSMART Extended Range: extending care for young patients
MiYOSMART Extended Range opens the door for more young patients to experience the proven benefits of MiYOSMART technology—clinically validated to slow myopia progression by an average of 60%². By managing myopia early, you can help reduce the risks of severe complications later in life.
The new MiYOSMART Extended Range tackles both functional and aesthetic challenges:
- Expanded power range. Accommodates prescriptions up to –13.00D, offering more possibilities than most options on the market so you can address higher levels of myopia effectively.
- Larger diameters. Provides greater flexibility for pairing lenses with a wider variety of frames, enhancing both functionality and style.
- Optimized lens edge thickness. Base curve and thickness optimization help address common aesthetic concerns that might discourage children from wearing their glasses consistently.
These enhancements give ECPs the tools to provide the best care possible to young patients across the myopic spectrum.
The critical role of early intervention in myopia management
If left untreated, myopia can lead to serious complications later in life, such as glaucoma, cataracts, and retinal detachment. These risks are significantly heightened for children with high myopia (prescriptions of –6.00D or more)³,⁴. The good news? Early intervention can make a significant difference, helping to slow the progression of myopia and reduce the risk of future complications.
However, until now, patients with higher prescriptions have had limited options for effective treatment. MiYOSMART Extended Range changes that. By addressing prescriptions up to –13.00D, this innovation allows ECPs to offer proven myopia management to a wider spectrum of young patients.
Every diopter counts
Each additional diopter of myopia significantly increases the risk of serious ocular complications. That’s why managing myopia early is essential to preserving long-term eye health. With MiYOSMART Extended Range, you can ensure no child’s prescription is overlooked and provide high myopes with the same level of care as other patients.
Building on MiYOSMART’s evidence-based technology
MiYOSMART Extended Range builds on the foundation of MiYOSMART’s industry-leading approach to myopia management.
Why ECPs trust MiYOSMART:
- Proven results: Clinically validated to slow myopia progression by an average of 60%, with 21.5% of patients showing no progression during a two-year study².
- Widely accepted technology: Uses DIMS Technology based on the peripheral hyperopic defocus theory, with sustained efficacy and no rebound effects⁵-⁷.
- Global recognition: Trusted worldwide, with over 10 million lenses sold in more than 40 countries and endorsements from leading experts and institutions⁸-¹².
- Expanded options: MiYOSMART lenses are now available in both clear and Sun solutions, offering UV and blue light protection for outdoor lifestyles. (Note: Extended Range is exclusively available in clear lenses.)
- Enhanced protection: With MiYOSMART Full Control, ECPs can provide an anti-reflective, scratch-resistant, and easy-to-clean coating with the added benefits of anti-bacterial and blue light control properties to show your patients that you put their wellbeing first.
HOYA Vision Care Canada remains committed to addressing the growing prevalence of myopia by equipping ECPs with innovative tools and technology. Together, we can make a meaningful impact in managing myopia in your community and improving the quality of life for your patients.
Talking points for your practice
As an ECP, you are your patients’ trusted expert, guiding them through decisions that can profoundly impact their eye health and quality of life. When it comes to myopia, your role is pivotal to helping educating families about effective solutions like MiYOSMART.
Here are a few conversation starters to help you engage your patients:
“Myopia is an important condition to treat – and early intervention matters.”
How to use it: Explain to parents that myopia is more than just nearsightedness. It’s a progressive condition that can lead to serious complications later in life if left unmanaged. Stress that intervening early, even in mild cases, can slow progression and reduce long-term risks.
“Every diopter counts.”
How to use it: Break down what a diopter is—a unit that measures the severity of nearsightedness. Each additional diopter of myopia increases the likelihood of serious complications. Highlight how MiYOSMART Extended Range is now available to address even higher prescriptions, ensuring every child has access to effective myopia management.
“We have solutions that work.”
How to use it: Reassure families with the evidence behind MiYOSMART lenses. Share that MiYOSMART is clinically proven to slow myopia progression. Mention the availability of Sun solutions for outdoor protection and the new Extended Range for higher prescriptions.
“We’re here to help your child’s vision now and in the future.”
How to use it: Position your practice as a partner in their child’s eye health journey. Explain that you’ll monitor their myopia progression and adjust treatments as needed, leveraging evidence-based innovations like MiYOSMART to give them the best possible outcomes.
We are committed to your success in discussing myopia and MiYOSMART solutions with your patients. For added support, please reach out to your Territory Manager for ideas and resources.
Partnering to tackle myopia together
As myopia rates continue to climb worldwide, your role as an ECP has never been more important. With MiYOSMART Extended Range, you can now provide proven myopia management to children with higher prescriptions, addressing a critical unmet need and helping protect their vision for the future.
HOYA Vision Care Canada is proud to lead the way in myopia treatment innovation, empowering you with solutions like MiYOSMART and the tools to make a difference in your practice and community. Together, we can ensure every child gets the care they deserve—because every diopter truly counts.
For more information about MiYOSMART Extended Range, or to access support and resources, contact your Territory Manager today.
References:
1 Brien Holden Vision Institute. Article at: Prevalence: 50% of the world myopic by 2050.
2 In 21.5% of the cases among children wearing MiYOSMART spectacle lens, during a 2-year randomized controlled clinical trial, no myopia progression was observed. Lam CSY, Tang WC, TseDY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739
3 Flitcroft D.I. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012 Nov; 31:622-660. http://dx/doi.org/10.1016/j.preteyeres.2012.06.004
4 Bullimore MA, Ritchey ER, Shah S, et al. The risks and benefits of myopia control. Ophthalmology. 2021;128:1561-79.
5 Nemeth J, Tapaszto B, Aclimandos WA, Kestelyn P, Jonas JB, De Faber JHN, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Eur J Ophthalmol. 2021;31(3):853-83.
6 Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci 2023;13(1):5475.
7 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical Br J Ophthalmol. 2020;104(3):363-8.
8 Based on number of MiYOSMART spectacle lenses sold per HOYA sales data on file as of October 2024.
9 Silmo Paris. Winners 2020. 2020. Available from: https://en.silmoparis.com/SILMO-d-OR/SILMO-d-Or-Awards/ 2020-Winners (Last accessed: 20/07/2023).
10 Inventions Geneva. Winners of the exhibition’s grand prix. 2023. Available from: https://inventions-geneva.ch/en/ grand-prix-en/ (Last accessed: 20/07/2023).
11 World Society of Paediatric Ophthalmology and Strabismus (WSPOS). Myopia Consensus Statement 2023. 2023. Available from: https://www.wspos.org/swdcore/uploads/WSPOS-Myopia-Consensus-Statement-2023-1.pdf (Last accessed: 20/07/2023).
12 Jong M, Jonas JB, Wolffsohn JS, Berntsen DA, Cho P, Clarkson-Townsend D, et al. IMI 2021 Yearly Digest. Invest Ophthalmol Vis Sci. 2021;62(5):7.